A Phase 1, Open label, Dose escalation and Dose expansion study of SCO-120 in HR +ve HER2-ve
advanced/ metastatic breast cancer (MBC) patients to evalaute the safety, tolerability and
prelimnary efficacy. Initial part with dose escalation is to determine the MTD and RP2D, and
PK and PD characterisation. RP2D will be further evalauted for prelimnary efficacy in MBC
patients with tretament failure on Aromatase Inhibitor/Fulvestrant/CDK4-6 inhibitors with or
with out ESR1 mutation.